Bausch + Lomb Corporation ( (BLCO) ) has issued an announcement.
Bausch + Lomb Corporation has announced a voluntary recall of certain intraocular lenses from its enVista platform due to reports of toxic anterior segment syndrome (TASS) following implantation. Although the reported cases are minimal and have responded well to treatment, the company has prioritized patient safety and is working to identify the root cause of the issue to restore the enVista platform to the market. Communications with eye care professionals are ongoing to manage the recall process effectively.
More about Bausch + Lomb Corporation
Bausch + Lomb is a global leader in eye health, offering a comprehensive portfolio of approximately 400 products, including contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products, and ophthalmic surgical devices and instruments. Founded in 1853, the company has a significant global presence with around 13,500 employees in approximately 100 countries, and is headquartered in Vaughan, Ontario.
YTD Price Performance: -12.94%
Average Trading Volume: 585,122
Technical Sentiment Signal: Buy
Current Market Cap: $5.6B
Find detailed analytics on BLCO stock on TipRanks’ Stock Analysis page.